Investor Newsletter

Issue 07 2021

MicroPort®

MicroPort® Shared the Use of Firehawk® and Firefighter™ in Complex Lesions at the 16th Ice City Conference of Cardiology (ICC2021)

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) recently participated in the virtual 16th Ice City Conference of Cardiology (ICC2021), presenting two real-time surgical operations using Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®) and Firefighter™ PTCA Balloon Dilatation Catheter (Firefighter™) in complex lesions, respectively. The conference was co-organized by Heilongjiang Medical Association and Heilongjiang Cardiology Society, and assisted by the Second Hospital Affiliated to Harbin Medical University and the Cardiovascular Disease Branch of Heilongjiang Medical Association.

Prof. Yu Li from Beijing Anzhen Hospital shared a real-time surgical operation case of combined use of Firehawk® in calcified bifurcation lesions. According to Prof. Li, the adoption of single-sided groove design and targeted drug-release technology allows Firehawk® stents to achieve the "gold standard" efficacy with only 1/3 of the drug loading of similar products – the lowest in the world. At the same time, Firehawk® stent has a complete coverage rate of 99.9%, which is highly safe and can reduce the occurrence of adverse events.

In the real-time surgery using Firefighter™ PTCA Balloon Dilatation Catheter in complex Lesions, Professor Jingang Cui from the Fuwai Hospital, affiliated to the National Cardiovascular Center, shared the clinical application of this product. According to Professor Cui, Firefighter™ PTCA balloon dilatation catheters are semi-compliant balloons specially designed for complex lesions, with the characteristics of being small, durable, fitting, and smooth. The extremely thin outer diameter allows for anastomotic manipulation within a 6F catheter, making it less prone to guidewire entanglement during multi-device manipulation. The new combination of patented fluorine-containing inner and outer catheters can avoid folding of the guidewire opening, which enhances the safety of operations. The catheters also have high pressure resistance and excellent crossability, which is conducive to the treatment of complex diseases in clinical use.

MicroPort® Cardiac Rhythm Management Business Announces US$150 Million Series C Investment

MicroPort Scientific Corporation ("MicroPort®") announced that MicroPort Cardiac Rhythm Management Limited ("MicroPort® CRM"), which is MicroPort®'s subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million. Hillhouse Capital Group and MicroPort® will co-lead the Series C investment and will invest US$20 million and US$47 million, respectively. Six new investors that will invest an additional US$83 million in capital include CICC, Country Garden Venture Capital (CGVC), YongRong Asset Management Ltd., L Squared Private Management, E Fund Management Co. Ltd., and Wanhui Capital. After the completion of this transaction, MicroPort® will continue to be the majority shareholder of MicroPort® CRM. The financing is expected to close in early August 2021, subject to customary closing conditions.

Mr. Benoit Clinchamps, President of MicroPort® CRM said: "MicroPort® CRM continues to grow its global revenue and advance its product pipeline to bring the best CRM technologies to treat patients affected by heart arrhythmias worldwide. We are excited about the growth opportunities that can be accessed in the next few years through this investment capital."

MicroPort

Endovastec™ Minos® Stent Graft System Completes First Clinical Implantation in Czech Republic

The first implantation of the Minos® Abdominal Aortic Stent-Graft and Delivery System (Minos® Stent Graft System), a product developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) was completed in the Czech Republic. This marks the twelfth market that the Minos® Stent Graft System has entered, following its approval for use in China, Greece, Poland, Spain, Germany, Italy, Switzerland, Argentina, Croatia, Hungary and Brazil.

The implantation procedure was performed by a surgical team led by Drs. Pavel Prochazka and Jozef Kučerák from the General Faculty Hospital. Preoperative angiographic examination showed that the patient, a 73-year-old male, had a challenging abdominal aortic aneurysm of approximately 6 cm in diameter, which is complicated by calcification and severe stenosis of the access artery. The team selected the Minos® Stent Graft System for treatment and performed post-dilation of the branch stent using a balloon, as the ultra-low profile delivery sheath of the Minos® Stent Graft System provides a better solution for patients with complicated abdominal aortic anatomy. Angiography showed that the aneurysm was effectively isolated, the stent graft well conformed to the patient's anatomy and the blood flow in the branch stent was restored, confirming the success of the operation.



MicroPort

First Implantation of Castor® Branched Stent-Graft System by MicroPort Endovastec™ Completed in Brazil

The first implantation of the Castor® Aortic Branched Stent-Graft and Delivery System (Castor®), developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), has been successfully completed in Brazil, marking the product's debut in the fifth overseas market, after Poland, Spain, Argentina and Italy.

The procedure was performed by a team led by Dr. Gustavo Paludetto of Brasília Hospital, Brazil. According to the CT angiography, there was an ulcer in the patient's aortic arch measuring approximately 11 mm in size, located at the opening of the left subclavian artery (LSA). The close proximity of the ulcer to the LSA meant that use of a regular tubular stent would result in an insufficient healthy landing zone at the distal end of the LSA. This would result in potential further ulcer lesions. Following comprehensive discussions, the surgical team opted to use the Castor® Stent for the procedure. The procedure was completed smoothly, the Castor® was precisely positioned and no endoleaks were observed.

MicroPort

Subject Enrollment Completed for the MicroPort® NeuroTech Tubridge® Vascular Reconstruction Device IMPACT Study

The last procedure of the IMPACT Study, a propsective, multicenter post-marketing surveillance study using the Tubridge® Vascular Reconstruction Device (Tubridge®), was recently performed at the First Affiliated Hospital of Zhengzhou University. The procedure marked the successful enrollment of all 200 subjects in the study since the first operation was completed on December 16, 2019.

The IMPACT study, co-led by the People's Hospital of Henan Province, Changhai Hospital Affiliated to the PLA Naval Medical University, and Beijing Tiantan Hospital affiliated to the Capital Medical University, involves 15 research centers, including the First Affiliated Hospital of Zhengzhou University, Zhujiang Hospital of Southern Medical University, the People's Hospital of Jiangsu Province, and the Second Affiliated Hospital of Nanchang University, to evaluate the safety and efficacy of Tubridge®.

MicroPort

CardioFlow Medtech Makes Follow-on Investment in Transcatheter Valve Start-up Valcare

MicroPort® CardioFlow Medtech Corporation (CardioFlow Medtech) has recently entered into a simple agreement for future equity (SAFE) with Valcare, Inc. (Valcare), a start-up focusing on innovative transcatheter technology, following the recent conclusion of CardioFlow Medtech's first investment via SAFE. Through this new agreement, CardioFlow Medtech will make an additional investment in Valcare of 2.48 million USD to support the program acceleration plan proposed by its management team. The investment will be converted to preferred equity at an agreed discount rate in the next capital raise.

Mr. Shuki Porath, CEO of Valcare, commented, "To date, three patients who have been enrolled in the clinical trial have received transseptal implants of the Amend™ annuloplasty ring. Results show a significant reduction in mitral regurgitation in these cases. We, therefore, have full confidence in the long-term performance of Amend™." He continued, "We believe this investment will further promote the development progress of Amend™, allowing it to provide a better treatment option for patients with mitral regurgitation in China and worldwide as soon as possible."

Commenting on the investment announcement, Mr. Guoming Chen, President of CardioFlow Medtech, stated, "The follow-on investment will further enrich the product line and R&D projects layout of CardioFlow Medtech. As we enhance and diversify our product portfolio, we will improve our competitiveness and ability to provide global patients with a complete medical solution for structural heart disease."

Subject Enrolment Completed for MicroPort® EP Cardiac Cryoablation System Trial

The IceMagic® Cardiac Cryoablation System (the IceMagic® system), developed by Shanghai MicroPort® EP MedTech Co., Ltd. (MicroPort® EP), was recently used in an atrial fibrillation ablation procedure at the General Hospital of the Northern Theater Command. This procedure marks the successful completion of subject enrolment of the IceMagic® system clinical trial since the first procedure was carried out in May 2020. Earlier in June 2021, the IceMagic® system entered the "Green Path", a special review process for innovative medical devices, after its application was approved by China's National Medical Products Administration (NMPA). The IceMagic® system is expected to become the first made-in-China cardiac cryoablation system licensed for marketing in China.

President of MicroPort® EP, Dr. Yiyong Sun, later extended his gratitude to the expert team for their support and guidance during the product R&D process, stating, "The completion of this clinical trial has laid the foundation for providing more patients with a new inclusive treatment solution."



MicroPort® Wewin Receives CE Mark for its 2019-nCoV PCR Test Kit

MicroPort® Wewin Diagnostics Co., Ltd (MicroPort® Wewin) recently received the CE mark for its self-developed real-time PCR test, SARS-CoV-2 Nucleic Acid Test Kit (PCR Test Kit).

The PCR Test Kit developed by MicroPort® Wewin is used for in vitro qualitative detection of 2019-nCoV nucleic acids in nasal and pharyngeal swab samples from suspected cases and cluster cases of COVID-19, as well as people who require a diagnosis or differential diagnosis of COVID-19. The PCR test kit is based on real-time RT-PCR technology, which provides a reliable diagnostic solution for medical professionals thanks to its high sensitivity, high specificity, anti-carry-over contamination system, and easy monitoring over the entire testing process.

MicroPort

MicroPort® Lifesciences Showcases Two Products at the 10th CSE Academic Conference on Diabetes and Gonadal Disorders

Shanghai MicroPort Lifesciences Co. (MicroPort® Lifesciences) recently presented the La Fenice® Insulin Pump and the La Fenice® Hypophyseal Hormone Infusion Pump at the 10th Academic Conference on Diabetes and Gonadal Disorders. The conference, organized by the Gonad Research Group and the Diabetes Research Group of the Chinese Society of Endocrinology recently.

Yimin Xu, Executive Director of MicroPort® Lifesciences, said, "We will continue to work towards the company's vision of building a brand that belongs to patients. We remain committed to independent innovation and development to provide patients with a total solution to their physiological needs using microinfusion technology as a core platform."

MicroPort

Investor Newsletter

Issue 07 2021

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com